Document is current
Any future updates will be listed below
-
Authors
Lynce, Filipa
Liu, Xianchen
Li, Benjamin
McRoy, Lynn
Chen, Connie
Liu, Raymond
Rugo, Hope S.
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 24 June 2025
First Online: 21 July 2025
Competing interests
: F.L. reports consulting/advisory role for AstraZeneca, Eli Lilly, Pfizer, Merck, and Daiichi Sankyo; and institutional research funding from Eisai, AstraZeneca, Zentalis, Merck, CytomX, and Gilead Sciences. R.L. reports travel, accommodation, and expenses from Pfizer and institutional research funding from Genentech, AstraZeneca, Exact Sciences, Biotheranostics, and BeiGene. H.S.R. reports consulting or advisory role for Napo Pharmaceuticals, Scorpion Therapeutics, Blueprint Medicines, and Puma Biotechnology; research funding for OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Astellas Pharma, Pionyr, Taiho Oncology, and GlaxoSmithKline; travel, accommodations, expenses for Merck, AstraZeneca, and Gilead Sciences. X.L., B.L., L.McR., and C.C. are employees of, and stockholders in, Pfizer Inc.
